Goldman Sachs Group assumed coverage on shares of Portola Pharmaceuticals (NASDAQ:PTLA) in a research note released on Friday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $75.00 price target on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the company. BidaskClub downgraded Portola Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, August 4th. Credit Suisse Group set a $70.00 price target on Portola Pharmaceuticals and gave the stock a hold rating in a research report on Thursday, August 10th. They noted that the move was a valuation call. Morgan Stanley reissued an overweight rating and set a $81.00 price target (up previously from $75.00) on shares of Portola Pharmaceuticals in a research report on Friday, October 6th. Oppenheimer reissued a buy rating and set a $80.00 price target on shares of Portola Pharmaceuticals in a research report on Tuesday, November 7th. Finally, Zacks Investment Research downgraded Portola Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, August 8th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $71.15.

Portola Pharmaceuticals (PTLA) opened at $52.63 on Friday. The company has a quick ratio of 8.31, a current ratio of 8.31 and a debt-to-equity ratio of 0.24. Portola Pharmaceuticals has a 1 year low of $17.48 and a 1 year high of $67.10.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.08. The company had revenue of $3.83 million during the quarter, compared to the consensus estimate of $4.71 million. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. Portola Pharmaceuticals’s revenue was down 58.9% compared to the same quarter last year. During the same quarter last year, the business posted ($1.64) earnings per share. analysts predict that Portola Pharmaceuticals will post -4.95 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of PTLA. Renaissance Technologies LLC acquired a new stake in shares of Portola Pharmaceuticals during the second quarter worth $21,187,000. Kornitzer Capital Management Inc. KS boosted its holdings in shares of Portola Pharmaceuticals by 38.7% during the third quarter. Kornitzer Capital Management Inc. KS now owns 727,812 shares of the biopharmaceutical company’s stock worth $39,324,000 after purchasing an additional 202,925 shares during the last quarter. Zevenbergen Capital Investments LLC boosted its holdings in shares of Portola Pharmaceuticals by 71.4% during the second quarter. Zevenbergen Capital Investments LLC now owns 452,190 shares of the biopharmaceutical company’s stock worth $25,400,000 after purchasing an additional 188,320 shares during the last quarter. Blue Jay Capital Management LLC acquired a new stake in shares of Portola Pharmaceuticals during the second quarter worth $6,740,000. Finally, State Street Corp boosted its holdings in shares of Portola Pharmaceuticals by 5.3% during the second quarter. State Street Corp now owns 2,085,838 shares of the biopharmaceutical company’s stock worth $117,164,000 after purchasing an additional 105,207 shares during the last quarter. Institutional investors and hedge funds own 87.45% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Goldman Sachs Group Initiates Coverage on Portola Pharmaceuticals (PTLA)” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://theolympiareport.com/2017/12/05/goldman-sachs-group-initiates-coverage-on-portola-pharmaceuticals-ptla.html.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Analyst Recommendations for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.